Seres Therapeutics Files Q1 2025 10-Q
Ticker: MCRB · Form: 10-Q · Filed: May 7, 2025 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, equity-plan
TL;DR
Seres Therapeutics Q1 2025 10-Q filed. Check equity plan updates.
AI Summary
Seres Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations. Key events include the filing date of May 7, 2025, and the reporting period of Q1 2025. The filing also references a subsequent event on April 10, 2025, related to an Amended and Restated 2025 Incentive Award Plan.
Why It Matters
This filing provides investors with an update on Seres Therapeutics' financial health and operational progress for the first quarter of 2025, including details on equity plans.
Risk Assessment
Risk Level: medium — The company operates in the volatile pharmaceutical sector, and the filing details financial performance and equity plan changes which can impact stock value.
Key Numbers
- Q1 2025 — Reporting Period (The period covered by the 10-Q filing.)
- 2025-03-31 — As of Date (The specific date for which financial information is reported.)
- 2025-05-07 — Filing Date (The date the report was officially submitted to the SEC.)
Key Players & Entities
- Seres Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250507 (date) — Filing date
- 0000950170-25-065173 (other) — Accession number for the filing
- 2025-04-10 (date) — Date of a subsequent event
- Amended and Restated Two Thousand And Twenty Five Incentive Award Plan (other) — A key subsequent event mentioned
FAQ
What is the primary purpose of this 10-Q filing for Seres Therapeutics, Inc.?
This 10-Q filing provides a quarterly update on Seres Therapeutics, Inc.'s financial condition and results of operations for the period ending March 31, 2025.
What is the accession number for this 10-Q filing?
The accession number for this filing is 0000950170-25-065173.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on May 7, 2025.
Does the filing mention any subsequent events?
Yes, the filing mentions a subsequent event on April 10, 2025, related to the Amended and Restated Two Thousand And Twenty Five Incentive Award Plan.
What is the fiscal year end for Seres Therapeutics, Inc.?
Seres Therapeutics, Inc.'s fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Seres Therapeutics, Inc. (MCRB).